Development of Dasatinib Nano-spanlastics and Assessment of Their Cytotoxicity

Abstract

The aim of this research is to develop Dasatinib nano-spanlastics as a novel drug delivery system and assess their cytotoxicity against cancer cells; the key issue being addressed is the efficacy and safety of these nanocarriers in enhancing the therapeutic effects of Dasatinib, necessitating the collection of in vitro cytotoxicity data and characterization metrics of the nano-spanlastics, including particle size, distribution, and drug release profiles. This dissertation explores the development of Dasatinib-loaded nano-spanlastics as an innovative drug delivery system aimed at enhancing the therapeutic efficacy and safety of Dasatinib in cancer treatment. The primary research question addresses the effectiveness of these nanocarriers in improving drug delivery through detailed in vitro cytotoxicity assessments alongside characterization of critical metrics such as particle size, distribution, and drug release profiles. The findings reveal that the formulated nano-spanlastics significantly increased the cytotoxic effects of Dasatinib on targeted cancer cells compared to standard delivery methods, demonstrating optimized release kinetics and favorable biocompatibility. Moreover, the particle size and uniform distribution of the nano-spanlastics were found to facilitate enhanced cellular uptake, leading to superior therapeutic outcomes. These significant results underline the potential of nanotechnology in developing advanced drug delivery systems that can improve treatment efficacy while minimizing adverse effects in cancer therapy. The implications of this study extend beyond the immediate context of Dasatinib, suggesting that nano-spanlastics may serve as a model for the modification and delivery of other anticancer therapies, thus contributing to the advancement of personalized medicine in oncology and ultimately improving patient outcomes in cancer care